ERBB2 and gastric cancer: Currently, systemic therapy for patients with HER-2 negative, unresectable advanced or recurrent gastric/gastroesophageal junction cancer (GC/GEJC) has been dominated by chemotherapy, and the common first-line agents include platinum, fluorouracil and taxane drugs worldwide (3–5).